A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 7, 2004, Pages 429-432

  Latte, Jenny ^a   Taverner, David ^a,b   Slobodian, Peter ^a   Shakib, Sepehr ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Acoustic rhinometry; Clinical trial; Coryza; Human; Placebo; Pseudoephedrine; Rhinomanometry

Indexed keywords

DECONGESTIVE AGENT; PSEUDOEPHEDRINE; SACCHARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPISTAXIS; FEMALE; HUMAN; MALE; NOSE AIRWAY RESISTANCE; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; RHINOMANOMETRY; RHINOMETRY; SINGLE DRUG DOSE; SYMPTOM; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; EPHEDRINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL DECONGESTANTS; NASAL OBSTRUCTION; REPRODUCIBILITY OF RESULTS; RHINOMETRY, ACOUSTIC; TIME FACTORS;

EID: 3843093956     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04013.x     Document Type: Article

References (14)

1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med. 2003; 163: 487-94.
2. Taverner D, Bickford L, Draper M. Nasal decongestants for the common cold. Cochrane Database Syst. Rev. 2000; 2: CD001953.
3. Taverner D, Bickford L, Shakib S, Tonkin A. Evaluation of the dose-response relationship for intra-nasal oxymetazoline hydrochloride in normal adults. Eur. J. Clin. Pharmacol. 1999; 55: 509-13.
4. Weir N. Acute and chronic inflammations of the nose. In: Mackay I, Bull T (eds). Scott-Brown's Otolaryngology - Rhinology. Butterworths, London. 1987; Ch. 8.
5. Hilberg O, Pedersen OF. Acoustic rhinometry: Recommendations for technical specifications and standard operating procedures [published erratum appears in Rhinology 2001; 39: 119]. Rhinology (Suppl.) 2000; 16: 3-17.
6. Clement PA. Committee report on standardization of rhinomanometry. Rhinology 1984; 22: 151-5.
7. Taverner D, Danz C, Economos D. The effects of oral pseudoephedrine on nasal patency in the common cold: A double-blind single-dose placebo-controlled trial. Clin. Otolaryngol. Allied Sci. 1999; 24: 47-51.
8. Diem K, Seldrup J. Random numbers table. In: Lentner C (ed.). Introduction to Statistics, Statistical Tables Mathematical Formulae. Geigy Scientific Tables, Volume 2, 8th edn. Ciba-Geigy, Basle. 1982; 167.
9. Bye CE, Cooper J, Empey DW et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ 1980; 281: 189-90.
10. Douglas RM, Chalker EB, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database Syst. Rev. 2000; 2: CD000980.
11. Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal anti-inflammatory agent in the treatment of experimental rhinovirus colds. Bull. N.Y. Acad. Med. 1989; 65: 145-60.
12. Turner RB. The treatment of rhinovirus infections: Progress and potential. Antiviral Res. 2001; 49: 1-14.
13. Rao SS, Hendley JO, Hayden FG, Gwaltney JM. Symptom expression in natural and experimental rhinovirus colds. Am. J. Rhinol. 1995; 9: 49-52.
14. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. 1. The common cold as a clinical entity. AMA Arch. Int. Med. 1958; 101: 267-78.